Centre Jean Perrin
Clermont-Ferrand, France
52 recruiting
Showing 1–20 of 64 trials
Recruiting
Phase 3
ADT +/- Darolutamide in de Novo Metastatic Prostate Cancer Patients With Vulnerable Functional Ability (PEACE6-Vulnerable)
Prostate Cancer Metastatic
UNICANCER300 enrolled95 locationsNCT04916613
Recruiting
Phase 3
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
Breast Cancer
Stemline Therapeutics, Inc.4,220 enrolled536 locationsNCT06492616
Recruiting
Phase 3
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
Metastatic Castration-resistant Prostate Cancer
Amgen750 enrolled125 locationsNCT07213674
Recruiting
Phase 3
Interest of Peri Operative CHemotherapy In Patients With CINSARC High-risk Localized Soft Tissue Sarcoma
Soft Tissue Sarcoma
Institut Claudius Regaud600 enrolled19 locationsNCT04307277
Recruiting
Phase 2
Niraparib With beVAcizumab After Complete cytoreductioN in Patients With ovArian Cancer
Ovarian Cancer
ARCAGY/ GINECO GROUP390 enrolled88 locationsNCT05183984
Recruiting
Phase 1Phase 2
A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers
Advanced Solid Tumors
Regeneron Pharmaceuticals933 enrolled57 locationsNCT04626635
Recruiting
Phase 1Phase 2
Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer
Prostate CancermCRPC (Metastatic Castration-resistant Prostate Cancer)Prostatic Neoplasms, Castration-Resistant+3 more
Celcuity Inc54 enrolled13 locationsNCT06190899
Recruiting
Phase 3
A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
Hoffmann-La Roche1,050 enrolled351 locationsNCT06065748
Recruiting
A Worldwide Cancer Registry Enrolling Participants Profiled With a Next-Generation Sequencing Test
Solid Tumours
Hoffmann-La Roche15,000 enrolled138 locationsNCT04529122
Recruiting
Phase 1Phase 2
Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
Breast NeoplasmsBreast DiseasesNeoplasms+5 more
Stemline Therapeutics, Inc.73 enrolled86 locationsNCT05386108
Recruiting
Phase 2
Pan Tumor Rollover Study
Cancer
Bristol-Myers Squibb1,500 enrolled399 locationsNCT03899155
Recruiting
Phase 3
Treatment Intensification With Temozolomide in Adults With a Glioblastoma
Glioblastoma
Centre Oscar Lambret486 enrolled19 locationsNCT03663725
Recruiting
Phase 2
Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread
Metastatic Urothelial Cancer
Gilead Sciences827 enrolled135 locationsNCT03547973
Recruiting
Phase 3
Chemotherapy De-escalation in HR +, HER2-, Intermediate-risk Early Breast Cancer Treated With Adjuvant Ribociclib
Breast Cancer
UNICANCER3,902 enrolled70 locationsNCT07237256
Recruiting
Phase 1Phase 2
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Breast CancerTriple-Negative Breast CancerColorectal, Cancer+26 more
PMV Pharmaceuticals, Inc300 enrolled76 locationsNCT04585750
Recruiting
Phase 3
Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)
Metastatic Castration-resistant Prostate Cancer
Amgen675 enrolled164 locationsNCT06691984
Recruiting
Phase 3
Flap Sparing in Postoperative Radiotherapy of Oral Cavity Cancers
Radiotherapy, AdjuvantOral Cavity CarcinomaFlap+1 more
Centre Francois Baclesse348 enrolled25 locationsNCT06798922
Recruiting
Phase 2
A Dose Finding Study of Debio 4228 in Participants With Advanced Prostate Cancer
Prostate Cancer
Debiopharm International SA66 enrolled37 locationsNCT06395753
Recruiting
Not Applicable
Study Evaluating DNA Double-strand Breaks (DSBs) REpair Factors (POLQ, Shieldin Complex and 53BP1) Expression as Biomarker of PARP Inhibitor Resistance in Patients With Deleterious Germline Mutation in BRCA 1/2 and HER2-negative, Metastatic or Locally Advanced Breast Cancer.
Breast Cancer
Institut Claudius Regaud120 enrolled25 locationsNCT05378204
Recruiting
Not Applicable
Identification of Genetic, Phenotypic, Clinical, Biological and Histological Factors Differentiating Patients With Ovarian Cancer Who Are Refractory to Platinum-based Therapy From Patients Defined as Long-term Responders to Platinum-based Therapy
Ovarian Cancer
Centre Jean Perrin55 enrolled1 locationNCT07361471